Non-invasive blood biomarkers for assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease

Figure 1 A suggested simplified algorithm for the use of non-invasive serum biomarkers for the assessment of patients with metabolic dysfunction-associated steatotic liver disease. ¹The cutoff value of fibrosis-4 for individuals ≥ 65 years old is adjusted to 2.0. MASLD: Metabolic dysfunction-associated steatotic liver disease; T2DM: Type 2 diabetes; FIB-4: Fibrosis-4; NFS: Non-alcoholic fatty liver disease fibrosis score; ELF: Enhanced liver fibrosis; APRI: Aspartate aminotransferase-to-platelet ratio index; ADAPT: Age, diabetes status, propeptide of type 3 collagen, and thrombocyte.